Jean-Charles Soria to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Jean-Charles Soria has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
1.983
-
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
Score: 0.330
-
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
Score: 0.330
-
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79(6):1257-1265.
Score: 0.320
-
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75.
Score: 0.253
-
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018 10; 52(4).
Score: 0.088
-
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 11; 104:1-8.
Score: 0.088
-
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori. 2018 Dec; 104(6):NP38-NP41.
Score: 0.085
-
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer. 2018 02 06; 118(3):344-352.
Score: 0.084
-
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
Score: 0.083
-
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer. 2018 01; 19(1):74-83.e11.
Score: 0.081
-
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer. 2017 08; 81:81-89.
Score: 0.081
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
Score: 0.079
-
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. Eur J Cancer. 2017 09; 83:194-202.
Score: 0.020
-
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
Score: 0.020
-
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017 Jun 20; 35(18):2018-2027.
Score: 0.020
-
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. Lung Cancer. 2017 06; 108:72-74.
Score: 0.020